DelMar Pharmaceuticals (NASDAQ:DMPI) received a $12.00 price target from analysts at HC Wainwright in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th.

DelMar Pharmaceuticals (NASDAQ:DMPI) opened at $1.68 on Thursday. DelMar Pharmaceuticals has a fifty-two week low of $0.78 and a fifty-two week high of $5.39. The firm has a market cap of $36.29, a price-to-earnings ratio of -2.46 and a beta of 1,227.20.

DelMar Pharmaceuticals (NASDAQ:DMPI) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). analysts predict that DelMar Pharmaceuticals will post -0.54 earnings per share for the current fiscal year.

In other news, CEO Saiid Zarrabian acquired 60,900 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was bought at an average price of $0.82 per share, with a total value of $49,938.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DMPI. Franklin Resources Inc. purchased a new position in DelMar Pharmaceuticals in the second quarter valued at $2,477,000. Sabby Management LLC acquired a new stake in shares of DelMar Pharmaceuticals in the second quarter valued at about $1,484,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of DelMar Pharmaceuticals in the third quarter valued at about $306,000. 16.91% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “DelMar Pharmaceuticals (DMPI) PT Set at $12.00 by HC Wainwright” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.